Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03515629
Title REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Regeneron Pharmaceuticals
Indications

lung non-small cell carcinoma

Therapies

Cemiplimab + Ipilimumab

Pembrolizumab

Age Groups: senior | adult
Covered Countries USA | ITA

Facility Status City State Zip Country Details
Regeneron Research Site Saint Petersburg Florida 33709 United States Details
Regeneron Research Site Cremona 26100 Italy Details
Regeneron Research Site Vilnius 08660 Lithuania Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field